HHS reports surge in drug prices over past year
Price increases for over 1,200 drugs exceeded inflation between July 2021 and July 2022, including many drugs used to treat cancer and other chronic conditions, the Department of Health and Human Services reported Friday. The increases on these drugs averaged 31.6%. Beginning in 2023, the Inflation Reduction Act requires drug manufacturers to pay rebates to Medicare if they enact price increases greater than inflation. The law also requires the federal government to negotiate prices for certain Medicare drugs with high spending. Between 2016 and 2021, drug spending growth was largely due to an increase in spending per prescription and a 43% increase in the cost of specialty drugs, according to another new HHS report.
Related News Articles
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program. “When…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…